- cafead Feb 28, 2024 at 10:02: PM
via After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels.
This year, the company is focused on growing its blockbuster hopeful Bimzelx and tacking on four extra indications for the psoriasis med, alongside other launches.
article source
This year, the company is focused on growing its blockbuster hopeful Bimzelx and tacking on four extra indications for the psoriasis med, alongside other launches.
article source